Tempus Next expands breast cancer support for guideline-based care

CHICAGO - Tempus AI, Inc. (NASDAQ:TEM), a $10 billion healthcare technology company showing impressive revenue growth of 43% over the past year, announced Tuesday the expansion of its Tempus Next care pathway intelligence platform to include breast cancer support. The platform, which has already screened thousands of lung cancer patients since its 2024 launch, will now address five different biomarker testing gaps specific to breast cancer. The company maintains a healthy gross profit margin of 57%, though InvestingPro analysis indicates it’s yet to achieve profitability.

The expanded platform aims to help physicians deliver guideline-directed medical care by identifying patients who may benefit from specific testing. Tempus Next integrates patient electronic medical record data with current clinical guidelines to surface potential care gaps.

Mercy, which operates over 1,000 physician practice locations across five states, has already implemented Tempus Next for both breast and lung cancer into its electronic medical record system.

"Staying current with rapidly evolving clinical guidelines—especially regarding biomarker testing like ESR1 mutations in metastatic breast cancer—remains a challenge for healthcare providers everywhere," said Dr. Jay Carlson, Medical Director of Oncology and Clinical Chair of Mercy Research.

Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus, noted that keeping up with complex and evolving clinical guidelines is particularly challenging for community physicians serving numerous patients daily.

The development of Tempus Next’s breast cancer module was funded by Tempus and one or more life sciences company sponsors, according to the company’s press release statement.

Tempus AI operates one of the world’s largest libraries of multimodal healthcare data, using artificial intelligence to support precision medicine applications for physicians and therapeutic development. With analyst price targets ranging from $55 to $75, investors seeking deeper insights can access the comprehensive Pro Research Report and 8 additional ProTips through InvestingPro, which currently indicates the stock may be trading above its Fair Value.

In other recent news, Tempus AI has announced a $400 million convertible senior notes offering, set to mature in 2030. The company plans to use the proceeds to repay $275 million in outstanding loans and fund capped call transactions to minimize stock dilution. Additionally, Tempus AI has entered a collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to advance Alzheimer’s disease research using its AI platform. In another development, TD Cowen analysts have maintained their Buy rating on Tempus AI, despite a recent short report raising concerns about the company’s revenue arrangements and transparency. The analysts believe the reaction to the report was exaggerated and remain confident in their rating. Furthermore, Tempus AI introduced a new liquid biopsy assay for monitoring cancer treatment response, presented at the American Society of Clinical Oncology Annual Meeting. This assay aims to track changes in circulating tumor DNA levels to assess the effectiveness of immune-checkpoint inhibitor therapy. Tempus AI expects the assay to be available for clinical use later this year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.